Discovery of the USP10-SKP2-Bcr-Abl axis not only represents an advance in cell biology in terms of understanding the regulation of Bcr-Abl signaling in the cell, provides new insight into the pathogenic mechanisms governing Bcr-Abl based CML, and identifies new potential drug targets for CML. Here, SKP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.